Hypoxia-Induced m6A modification via YTHDF2 stabilizes PFKL to fuel MDSC Glycolysis and hepatocellular carcinoma progression

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Functional & Integrative Genomics

• Publication date

  2025-11-13

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s10142-025-01743-6PMID 41225244
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Current status and issues of colorectal cancer screening - toward the introduction of colonoscopy into the population-based screening program].

  2024cited by this paper
• METTL16 promotes liver cancer stem cell self-renewal via controlling ribosome biogenesis and mRNA translation

  2024cited by this paper
• YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD‐L1/VEGFA Axis

  2024cited by this paper
• Myeloid-derived suppressor cells in cancer and cancer therapy

  2024cited by this paper
• Phosphorylation of PFKL regulates metabolic reprogramming in macrophages following pattern recognition receptor activation

  2024cited by this paper
• The tumor-intrinsic role of the m6A reader YTHDF2 in regulating immune evasion

  2024cited by this paper
• Functional states of myeloid cells in cancer.

  2023cited by this paper
• Current understanding of cancer stem cells: Immune evasion and targeted immunotherapy in gastrointestinal malignancies

  2023cited by this paper
• The N6-methyladenosine METTL3 regulates tumorigenesis and glycolysis by mediating m6A methylation of the tumor suppressor LATS1 in breast cancer

  2023cited by this paper
• Role of tumor microenvironment in cancer progression and therapeutic strategy

  2023influential reference
• The Role of Tumor Metabolic Reprogramming in Tumor Immunity

  2023cited by this paper
• Targeting the mechano-microenvironment and liver cancer stem cells: a promising therapeutic strategy for liver cancer

  2023cited by this paper
• YTHDF2 inhibition potentiates radiotherapy anti-tumor efficacy

  2023influential reference
• The m6A Reader YTHDF2 Promotes Bladder Cancer Progression by Suppressing RIG-I–Mediated Immune Response

  2023cited by this paper
• The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth.

  2023cited by this paper
• Lactylation-driven METTL3-mediated RNA m6A modification promotes immunosuppression of tumor-infiltrating myeloid cells.

  2022cited by this paper
• Global burden of primary liver cancer in 2020 and predictions to 2040

  2022cited by this paper
• Recent Advances in Systemic Therapy for Hepatocellular Carcinoma.

  2022cited by this paper
• m6A binding protein YTHDF2 in cancer

  2022cited by this paper
• Recent advances in systemic therapy for hepatocellular carcinoma

  2022cited by this paper
• MDSC: Markers, development, states, and unaddressed complexity.

  2021cited by this paper
• The biological function of m6A reader YTHDF2 and its role in human disease

  2021cited by this paper
• The role of m6A modification in the biological functions and diseases

  2021cited by this paper
• Mechanisms Underlying the Role of Myeloid-Derived Suppressor Cells in Clinical Diseases: Good or Bad

  2021cited by this paper
• Emerging Regulatory Mechanisms Involved in Liver Cancer Stem Cell Properties in Hepatocellular Carcinoma

  2021cited by this paper
• Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer

  2021cited by this paper
• Targeting PFKL with penfluridol inhibits glycolysis and suppresses esophageal cancer tumorigenesis in an AMPK/FOXO3a/BIM-dependent manner

  2021cited by this paper
• The RNA m6A reader YTHDF2 maintains oncogene expression and is a targetable dependency in glioblastoma stem cells.

  2020cited by this paper
• Tumor microenvironment complexity and therapeutic implications at a glance

  2020cited by this paper
• Challenges in liver cancer and possible treatment approaches.

  2020cited by this paper
• YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer

  2020cited by this paper
• Cancer stemness in hepatocellular carcinoma: mechanisms and translational potential

  2020cited by this paper
• A20 targets PFKL and glycolysis to inhibit the progression of hepatocellular carcinoma

  2020cited by this paper
• Molecular Mechanisms Driving mRNA Degradation by m6A Modification.

  2020cited by this paper
• Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics

  2019cited by this paper
• YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma.

  2019cited by this paper
• Quantitative Tracking Tumor Suppression Efficiency of Human Umbilical Cord-Derived Mesenchymal Stem Cells by Bioluminescence Imaging in Mice Hepatoma Model

  2019cited by this paper
• Tumor microenvironment components: Allies of cancer progression.

  2019cited by this paper
• Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape

  2019cited by this paper
• Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma.

  2018cited by this paper
• Suppression of m6A reader Ythdf2 promotes hematopoietic stem cell expansion

  2018cited by this paper
• Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

  2018cited by this paper
• HIF1α and metabolic reprogramming in inflammation.

  2016cited by this paper
• Cancer and liver cirrhosis: implications on prognosis and management

  2016cited by this paper
• Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.

  2015cited by this paper
• Immune evasion in cancer: Mechanistic basis and therapeutic strategies.

  2015cited by this paper
• Cancer stem cells in the development of liver cancer.

  2013cited by this paper
• Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13.

  2010influential reference
• Perioperative management of the patient with liver disease and management of the chronic alcoholic.

  2006cited by this paper
• Publisher's Note

  2003cited by this paper

• No citing papers are available for this paper.